Literature DB >> 32967465

Intravitreal injections during COVID-19 outbreak: Real-world experience from an Italian tertiary referral center.

Adriano Carnevali1, Giuseppe Giannaccare1, Valentina Gatti1, Gianfranco Scuteri1, Giorgio Randazzo1, Vincenzo Scorcia1.   

Abstract

We report our experience during COVID-19 outbreak for intravitreal injections in patients with maculopathy. We proposed a treatment priority levels and timings; the "High" priority level includes all monocular patients; the "Moderate" is assigned to all patients with an active macular neovascularization; the patients affected by diabetic macular edema or retinal vein occlusion belong to the "Low" class. This organization allowed us to treat the most urgent patients although the injections performed had a 91.7% drop compared to the same period of 2019.

Entities:  

Keywords:  Age-related macular degeneration; central serous chorioretinopathy; diabetic macular edema; practice management; retina; retina – medical therapies; socioeconomics and education in medicine/ophthalmology; venous occlusive disease

Mesh:

Substances:

Year:  2020        PMID: 32967465     DOI: 10.1177/1120672120962032

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  12 in total

1.  Comparison of intravitreal aflibercept and dexamethasone implant in the treatment of macular edema associated with diabetic retinopathy or retinal vein occlusion: a Meta-analysis and systematic review.

Authors:  Xuan-Yu Qiu; Xiao-Fei Hu; Ya-Zhou Qin; Ji-Xian Ma; Qiu-Ping Liu; Li Qin; Jing-Ming Li
Journal:  Int J Ophthalmol       Date:  2022-09-18       Impact factor: 1.645

Review 2.  Applications and Current Medico-Legal Challenges of Telemedicine in Ophthalmology.

Authors:  Daniela Mazzuca; Massimiliano Borselli; Santo Gratteri; Giovanna Zampogna; Alessandro Feola; Marcello Della Corte; Francesca Guarna; Vincenzo Scorcia; Giuseppe Giannaccare
Journal:  Int J Environ Res Public Health       Date:  2022-05-05       Impact factor: 4.614

Review 3.  Retina in the Age of COVID-19.

Authors:  Samuel Gelnick; Marib Akanda; Ronni Lieberman
Journal:  Adv Ophthalmol Optom       Date:  2021-04-27

4.  Evolving Treatment Paradigm in the Management of Diabetic Macular Edema in the Era of COVID-19.

Authors:  Claudio Iovino; Enrico Peiretti; Giuseppe Giannaccare; Vincenzo Scorcia; Adriano Carnevali
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

5.  Short-Term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits.

Authors:  Noy Ashkenazy; Lediana Goduni; William E Smiddy
Journal:  Clin Ophthalmol       Date:  2021-02-03

6.  Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration.

Authors:  Joel Hanhart; Rony Wiener; Hashem Totah; Evgeny Gelman; Yishay Weill; Adi Abulafia; David Zadok
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-01-11       Impact factor: 3.535

7.  Impact of the COVID-19 pandemic's first wave on the care and treatment situation of intravitreal injections in a German metropolitan region.

Authors:  Birthe Stemplewitz; Joel Luethy; Ulrich Schaudig; Marc Schargus; Mau-Thek Eddy; Martin Spitzer; Ulrike Brocks; Julie Kieckhoefel; Christa Schneemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-01-10       Impact factor: 3.535

8.  OCT-Angiography Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Dexamethasone Implant.

Authors:  Pablo Carnota-Méndez; Carlos Méndez-Vázquez; Conchi Pérez-Gavela
Journal:  Clin Ophthalmol       Date:  2022-02-02

Review 9.  The Impact of COVID-19 on Diabetic Retinopathy Monitoring and Treatment.

Authors:  Ishrat Ahmed; T Y Alvin Liu
Journal:  Curr Diab Rep       Date:  2021-09-08       Impact factor: 4.810

10.  The Impact of Non-Ophthalmic Factors on Intravitreal Injections During the COVID-19 Lockdown.

Authors:  Sahar Ashrafzadeh; Bradley S Gundlach; Irena Tsui
Journal:  Clin Ophthalmol       Date:  2021-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.